Abstracts tagged "pain"

Abstract Number: 0796 • ACR Convergence 2024
Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Carlos Raul Ramirez Medina¹, Mark Lunt², David Jenkins², William Dixon², Niels Peek³ and Meghna Jani², ¹The University of Manchester, Warrington, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³THIS Institute , University of Cambridge, Cambridge, United Kingdom
Background/Purpose: England has seen a notable rise in prescription opioid use over the past two decades, leading to some of Europe's highest opioid-related hospital admissions.…
Abstract Number: 1211 • ACR Convergence 2024
An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain
Thor Ostenfeld¹, Stefan Ivanicius¹, Roman Stancik² and Philip G Conaghan³, ¹Grunenthal GmbH, Aachen, Germany, ²National Institute of Rheumatic Diseases, Piestany, Slovenia, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: The transient receptor potential vanilloid 1 (TRPV1) is a critical driver of osteoarthritis (OA) pain. RTX-GRT7039 is an investigational medicinal product containing the active…
Abstract Number: 1234 • ACR Convergence 2024
Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration
Nadine Henderson¹, Claud Theakston¹, Sulayman Chowhury¹, David Mott¹, Chris Skedgel¹, rita Freitas², Stefan Ivanicius³, Gudula Petersen³, Samantha Schofield³, Angie Botto-van Bemden⁴, Mickaël Hiligsmann⁵, Ricardo larrainzar⁶, Deborah Marshall⁷, Tommi Tervonen⁸ and David Walsh⁹, ¹Office of Health Economics, London, United Kingdom, ²Grünenthal GmbH, Aachen, Germany, ³Grunenthal GmbH, Aachen, Germany, ⁴Musculosketal Research International, Miami, FL, ⁵Maastricht University, Maastricht, Netherlands, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷University of Calgary, Calgary, AB, Canada, ⁸Kielo Research, Zug, Switzerland, ⁹University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Knee osteoarthritis (KOA) is a leading global cause of disability and chronic pain (Cross et al., 2014). It is well established that KOA affects…
Abstract Number: 2091 • ACR Convergence 2024
Changes in Analgesic Prescriptions for the Treatment of Osteoarthritis During the COVID-19 Pandemic
Derek Ochi¹, Dagoberto Pina², Manmeet Kaur³, Jeffery Fine⁴, Daniel Black⁵ and Barton Wise⁶, ¹Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis, Sacramento, CA, ²School of Medicine, University of California Davis, Sacramento, CA, ³Division of Rheumatology, Allergy and Immunology, University of California San Diego, San Diego, CA, ⁴Department of Public Health Sciences, University of California Davis, Sacramento, CA, ⁵Innovation Technology - Data Center of Excellence, University of California Davis, Sacramento, CA, ⁶Division of Rheumatology, Allergy and Clinical Immunology, University of California Davis and Department of Orthopaedic Surgery, University of California Davis, Sacramneto, CA
Background/Purpose: Osteoarthritis (OA) is a leading cause of disability. The 2019 American College of Rheumatology (ACR)/Arthritis Foundation (AF) Guideline for the Management of OA recommends…
Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Philip Mease¹, Christopher Ritchlin², Lu Gao³, Peter Schafer⁴, Miroslawa Nowak³, Ian M. Catlett³ and Jinqi Liu³, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, BELLE MEAD, NJ
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…
Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Samuel Govea-Peláez¹, Beatriz Alcalá-Carmona², Jennifer Balderas Miranda³, Yatzil Reyna-Juárez², María José Ostos-prado², Nancy R Mejía-Domínguez², Guillermo Juarez-Vega⁴, Jiram Torres Ruiz⁵ and Diana Gomez-martin⁶, ¹INCMNSZ, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
Abstract Number: 0797 • ACR Convergence 2024
Associations Between Discordance of Disease Activity Indices and Quantitative Sensory Testing Measures of Nociplastic Pain in Patients with Early Rheumatoid Arthritis
Clarice Lin¹, Burcu Aydemir¹, Jing Song², Lutfiyya Muhammad³, Tuhina Neogi⁴, Wendy Marder⁵, Clifton Bingham⁶, Marcy Bolster⁷, Daniel Clauw⁸, Dorothy Dunlop⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Worthington, MN, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Johns Hopkins University, Baltimore, MD, ⁷Massachusetts General Hospital, Boston, MA, ⁸University of Michigan, Whitmore Lake, MI, ⁹Northwestern University, New Haven, CT
Background/Purpose: Approximately one-third of patients with rheumatoid arthritis (RA) experience nociplastic pain, a type of pain that occurs due to abnormalities in the way the…
Abstract Number: 1212 • ACR Convergence 2024
Childhood Maltreatment Increases Risk of Chronic Widespread Pain: Counterfactual Analysis of UK Biobank
Kate Timmins¹, Tim Hales² and Gary Macfarlane¹, and The Consortium Against Pain inEquality Investigators and Advisory Group, ¹University of Aberdeen, Aberdeen, United Kingdom, ²University of Dundee, Dundee, United Kingdom
Background/Purpose: Adverse childhood experiences (ACEs), including maltreatment (abuse and neglect), have been associated with chronic pain, but the evidence is largely cross-sectional. Existing evidence is…
Abstract Number: 1335 • ACR Convergence 2024
The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA
Charis Meng¹, Margaret Butler¹, Deanna Jannat-Khah¹, Yvonne Lee², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University, Chicago, IL, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Non-articular pain (NAP) is often reported by early RA (eRA) patients, impacts RA remission (REM) but remains poorly defined and this hampers RA care.…
Abstract Number: 2092 • ACR Convergence 2024
Remote-Delivered Tai Chi and Gut Microbiota in Osteoarthritis: A Randomized Mechanistic Trial
Chenchen Wang¹, Timothy McAlindon², Meghan Short¹, Mei Chung³, Ye Chen¹, Albert Tai¹ and Honorine Ward¹, ¹Tufts Medical Center, Boston, MA, ²University of Massachusets, Worchester, MA, ³Tufts Medical Center, Brighton, MA
Background/Purpose: Previous studies show that Tai Chi achieves clinical improvement for osteoarthritis (OA) through multiple pathways. There is evidence for interaction of the gut microbiota…
Abstract Number: 2368 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Philip Mease¹, William Tillett², Maarten de Wit³, Laure Gossec⁴, M. Elaine Husni⁵, Fabian Proft⁶, Barbara Ink⁷, Rajan Bajracharya⁷, Jason Coarse⁸, Jérémy Lambert⁹, Laura Coates¹⁰ and Alice Gottlieb¹¹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³Stichting Tools, Patient Research Partner, Amsterdam, Netherlands, ⁴Sorbonne Université, Paris, France, ⁵Cleveland Clinic, Cleveland, OH, ⁶Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Morrisville, NC, ⁹UCB Pharma, Colombes, France, ¹⁰University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ¹¹Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: PsA significantly impacts patients' quality of life due to functional limitations, pain, and fatigue.1 Sustained relief from pain and fatigue are therefore important aims…
Abstract Number: 0349 • ACR Convergence 2024
Impact of the Stanford University Chronic Pain Self-Management Education Program on Pain Severity, Pain Self-Efficacy, and Pain Disability in a Population with a High Prevalence of Arthritis
Dina Jones¹, Louise Murphy², Ranjita Misra¹, Teresa Brady³, Sijin Wen¹, Dana Guglielmo⁴, Maura Robinson¹, Samantha Shawley-Brzoska¹, Chong Li¹, Alison Vargovich⁵, Megan Burkart⁶ and Richard Vaglienti¹, ¹West Virginia University, Morgantown, WV, ²Consultant, Halifax, NS, Canada, ³Clarity Consulting and Communications, Atlanta, GA, ⁴Consultant, Los Angeles, CA, ⁵Private Practice, Buffalo, NY, ⁶West Virginia Unviverstiy, Morgantown, WV
Background/Purpose: In 2021, 51.6 million (20.9%) US adults reported chronic pain (CP). Arthritis is a leading cause of CP. The Stanford Chronic Pain Self-Management Program…
Abstract Number: 0798 • ACR Convergence 2024
Acute Activation of the Rat Dorsal Root Ganglion Nociceptive Cells by the Serum of Patients Suffering from Fibromyalgia
Francisco Mercado¹, Pedro Segura-Chama¹, Angélica Almanza¹, Laura Aline Martinez-Martinez² and Manuel Martinez-Lavin³, ¹Instituto Nacional De Psiquiatría Ramon de la Fuente Muñiz, Mexico City, Mexico, ²Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico, ³Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico
Background/Purpose: A consistent line of investigation proposes fibromyalgia as a stress-evoked sympathetically maintained neuropathic pain syndrome. This theory posits dorsal root ganglia (DRG) at the…
Abstract Number: 1213 • ACR Convergence 2024
High Prevalence of and Medication Use in Musculoskeletal and Chronic Multisite Pain in Community-Dwelling Older Adults: The Framingham Heart Study
Sayali Dhamne¹, Robert Edwards², Emelia Benjamin³, Sarah Tilley³, Angelo Demalia⁴, Margaret Clancy³, Mary Molly Gheller³ and Tuhina Neogi³, ¹Boston University Chobantian & Avedisian School of Medicine, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Framingham Heart Study, Boston, MA
Background/Purpose: Over 100 million adults have chronic pain, largely affecting older adults who often have >1 chronic pain condition. Traditionally, chronic overlapping pain conditions (COPC)…
Abstract Number: 1380 • ACR Convergence 2024
Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib
Manish Jain¹, Arthur Kavanaugh², Angela Crowley³, Avani Joshi⁴, Patrick Zueger⁵, Diane Caballero⁶, Andrew Garrison⁶ and Peter C. Taylor⁷, ¹Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, ²University of California San Diego, La Jolla, CA, ³Illinois Bone and Joint Institute, Hinsdale Orthopaedics, Hinsdale, IL, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Inc., North Chicago, IL, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: Pain is a crucial symptom for patients with RA; early and effective treatment can help alleviate it.1 In this post hoc analysis, we investigated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].